Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism

Peptides

Volumn 100, Issue , 2018, Pages 94-100

  Al Batran, Rami ^a,b   Almutairi, Malak ^a,b   Ussher, John R ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Energy metabolism; Fatty acid oxidation; Glucagon; Glucagon like peptide 1; Glucagon like peptide 1 receptor; Glucose oxidation; Heart; Insulin

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE;

ARTICLE; CARDIAC ENERGY METABOLISM; CARDIAC MUSCLE CELL; ENERGY METABOLISM; FATTY ACID OXIDATION; GLUCAGON RELEASE; GLUCOSE OXIDATION; HEART; HEART PROTECTION; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SYSTEMIC THERAPY; AGONISTS; ANIMAL; CARDIAC MUSCLE; CARDIOVASCULAR SYSTEM; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

ANIMALS; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; FATTY ACIDS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; HUMANS; INSULIN; MYOCARDIUM; OXIDATION-REDUCTION;

EID: 85041479468     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2017.12.005     Document Type: Article

References (83)

1. Ali, S., Ussher, J.R., Baggio, L.L., Kabir, M.G., Charron, M.J., Ilkayeva, O., et al. Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol. Metab. 4 (2015), 132–143.
2. Aravindhan, K., Bao, W., Harpel, M.R., Willette, R.N., Lepore, J.J., Jucker, B.M., Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart. PLoS One, 10, 2015, e0130894.
3. Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157.
4. Ban, K., Noyan-Ashraf, M.H., Hoefer, J., Bolz, S.S., Drucker, D.J., Husain, M., Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and −independent pathways. Circulation 117 (2008), 2340–2350.
5. Bao, W., Aravindhan, K., Alsaid, H., Chendrimada, T., Szapacs, M., Citerone, D.R., et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One, 6, 2011, e23570.
6. Bhashyam, S., Fields, A.V., Patterson, B., Testani, J.M., Chen, L., Shen, Y.T., et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ. Heart Fail 3 (2010), 512–521.
7. Boudina, S., Abel, E.D., Diabetic cardiomyopathy revisited. Circulation 115 (2007), 3213–3223.
8. Brownsey, R.W., Boone, A.N., Allard, M.F., Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc. Res. 34 (1997), 3–24.
9. Buchanan, J., Mazumder, P.K., Hu, P., Chakrabarti, G., Roberts, M.W., Yun, U.J., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146 (2005), 5341–5349.
10. Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17 (2013), 819–837.
11. Ciapponi, A., Pizarro, R., Harrison, J., Trimetazidine for stable angina. Cochrane Database Syst. Rev.(Issue 4), 2005, 10.1002/14651858.CD003614.pub2 Art. No.: CD003614.
12. Constantin-Teodosiu, D., Constantin, D., Stephens, F., Laithwaite, D., Greenhaff, P.L., The role of FOXO and PPAR transcription factors in diet-mediated inhibition of PDC activation and carbohydrate oxidation during exercise in humans and the role of pharmacological activation of PDC in overriding these changes. Diabetes 61 (2012), 1017–1024.
13. Cunningham, C.H., Lau, J.Y., Chen, A.P., Geraghty, B.J., Perks, W.J., Roifman, I., et al. Hyperpolarized 13C metabolic MRI of the human heart: initial experience. Circ. Res. 119 (2016), 1177–1182.
14. DeFronzo, R.A., Ferrannini, E., Groop, L., Henry, R.R., Herman, W.H., Holst, J.J., et al. Type 2 diabetes mellitus. Nat. Rev. Dis. Primers, 1, 2015, 15019.
15. Drucker, D.J., The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 24 (2016), 15–30.
16. Finck, B.N., Lehman, J.J., Leone, T.C., Welch, M.J., Bennett, M.J., Kovacs, A., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109 (2002), 121–130.
17. Folmes, C.D., Clanachan, A.S., Lopaschuk, G.D., Fatty acids attenuate insulin regulation of 5'-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circ. Res. 99 (2006), 61–68.
18. Gopal, K., Saleme, B., Al Batran, R., Aburasayn, H., Eshreif, A., Ho, K.L., et al. FoxO1 regulates myocardial glucose oxidation rates via transcriptional control of pyruvate dehydrogenase kinase 4 expression. Am. J. Physiol. Heart Circ. Physiol. 313 (2017), H479–H490.
19. Holst, J.J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (2007), 1409–1439.
20. How, O.J., Aasum, E., Severson, D.L., Chan, W.Y., Essop, M.F., Larsen, T.S., Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55 (2006), 466–473.
21. Jaswal, J.S., Ussher, J.R., Lopaschuk, G.D., Myocardial fatty acid utilization as a determinant of cardiac efficiency and function. Clin. Lipidol. 4 (2009), 379–389.
22. Kahn, S.E., Cooper, M.E., Del Prato, S., Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383 (2014), 1068–1083.
23. Kim, M., Platt, M.J., Shibasaki, T., Quaggin, S.E., Backx, P.H., Seino, S., et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19 (2013), 567–575.
24. Lamont, B.J., Li, Y., Kwan, E., Brown, T.J., Gaisano, H., Drucker, D.J., Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J. Clin. Invest. 122 (2012), 388–402.
25. Le Page, L.M., Rider, O.J., Lewis, A.J., Ball, V., Clarke, K., Johansson, E., et al. Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study. Diabetes 64 (2015), 2735–2743.
26. Lepore, J.J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A.M., et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail. 4 (2016), 559–566.
27. Liu, Q., Docherty, J.C., Rendell, J.C., Clanachan, A.S., Lopaschuk, G.D., High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J. Am. Coll. Cardiol. 39 (2002), 718–725.
28. Lonborg, J., Kelbaek, H., Vejlstrup, N., Botker, H.E., Kim, W.Y., Holmvang, L., et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ. Cardiovasc. Interv. 5 (2012), 288–295.
29. Lonborg, J., Vejlstrup, N., Kelbaek, H., Botker, H.E., Kim, W.Y., Mathiasen, A.B., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33 (2012), 1491–1499.
30. Lopaschuk, G.D., Ussher, J.R., Folmes, C.D., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90 (2010), 207–258.
31. Lopaschuk, G.D., Witters, L.A., Itoi, T., Barr, R., Barr, A., Acetyl-CoA carboxylase involvement in the rapid maturation of fatty acid oxidation in the newborn rabbit heart. J. Biol. Chem. 269 (1994), 25871–25878.
32. Ma, J., Hart, G.W., Protein O-GlcNAcylation in diabetes and diabetic complications. Expert Rev. Proteomics. 10 (2013), 365–380.
33. Macaulay, S.L., Jarett, L., Insulin mediator causes dephosphorylation of the alpha subunit of pyruvate dehydrogenase by stimulating phosphatase activity. Arch. Biochem. Biophys. 237 (1985), 142–150.
34. Mansor, L.S., Sousa Fialho, M.D.L., Yea, G., Coumans, W.A., West, J.A., Kerr, M., et al. Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation. Cardiovasc. Res. 113 (2017), 737–748.
35. Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375 (2016), 1834–1844.
36. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375 (2016), 311–322.
37. Moberly, S.P., Mather, K.J., Berwick, Z.C., Owen, M.K., Goodwill, A.G., Casalini, E.D., et al. Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res. Cardiol., 108, 2013, 365.
38. Monji, A., Mitsui, T., Bando, Y.K., Aoyama, M., Shigeta, T., Murohara, T., Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 305 (2013), H295–304.
39. Mulvihill, E.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr. Rev. 35 (2014), 992–1019.
40. Neely, J.R., Morgan, H.E., Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu. Rev. Physiol. 36 (1974), 413–459.
41. Nikolaidis, L.A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110 (2004), 955–961.
42. Nikolaidis, L.A., Elahi, D., Shen, Y.T., Shannon, R.P., Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289 (2005), H2401–8.
43. Nikolaidis, L.A., Mankad, S., Sokos, G.G., Miske, G., Shah, A., Elahi, D., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004), 962–965.
44. Noyan-Ashraf, M.H., Momen, M.A., Ban, K., Sadi, A.M., Zhou, Y.Q., Riazi, A.M., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58 (2009), 975–983.
45. Noyan-Ashraf, M.H., Shikatani, E.A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.K., et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127 (2013), 74–85.
46. Panjwani, N., Mulvihill, E.E., Longuet, C., Yusta, B., Campbell, J.E., Brown, T.J., et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 154 (2013), 127–139.
47. Patel, M.S., Korotchkina, L.G., Regulation of the pyruvate dehydrogenase complex. Biochem. Soc. Trans. 34 (2006), 217–222.
48. Patel, M.S., Nemeria, N.S., Furey, W., Jordan, F., The pyruvate dehydrogenase complexes: structure-based function and regulation. J. Biol. Chem. 289 (2014), 16615–16623.
49. Peterson, L.R., Herrero, P., Schechtman, K.B., Racette, S.B., Waggoner, A.D., Kisrieva-Ware, Z., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109 (2004), 2191–2196.
50. Poornima, I., Brown, S.B., Bhashyam, S., Parikh, P., Bolukoglu, H., Shannon, R.P., Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ. Heart Fail 1 (2008), 153–160.
51. Popp, D.A., Kiechle, F.L., Kotagal, N., Jarett, L., Insulin stimulation of pyruvate dehydrogenase in an isolated plasma membrane-mitochondrial mixture occurs by activation of pyruvate dehydrogenase phosphatase. J. Biol. Chem. 255 (1980), 7540–7543.
52. Qaseem, A., Humphrey, L.L., Sweet, D.E., Starkey, M., Shekelle, P., Clinical Guidelines Committee of the American College of P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 156 (2012), 218–231.
53. Randle, P.J., Garland, P.B., Hales, C.N., Newsholme, E.A., The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963), 785–789.
54. Read, P.A., Hoole, S.P., White, P.A., Khan, F.Z., O'Sullivan, M., West, N.E., et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv. 4 (2011), 266–272.
55. Read, P.A., Khan, F.Z., Dutka, D.P., Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 98 (2012), 408–413.
56. Richards, P., Parker, H.E., Adriaenssens, A.E., Hodgson, J.M., Cork, S.C., Trapp, S., et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63 (2014), 1224–1233.
57. Rijzewijk, L.J., van der Meer, R.W., Lamb, H.J., de Jong, H.W., Lubberink, M., Romijn, J.A., et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J. Am. Coll. Cardiol. 54 (2009), 1524–1532.
58. Saddik, M., Lopaschuk, G.D., Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J. Biol. Chem. 266 (1991), 8162–8170.
59. Sassoon, D.J., Tune, J.D., Mather, K.J., Noblet, J.N., Eagleson, M.A., Conteh, A.M., et al. Glucagon-like peptide 1 receptor activation augments cardiac output and improves cardiac efficiency in obese swine after myocardial infarction. Diabetes 66 (2017), 2230–2240.
60. Shimizu, I., Yoshida, Y., Katsuno, T., Tateno, K., Okada, S., Moriya, J., et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab. 15 (2012), 51–64.
61. Smith, E.P., An, Z., Wagner, C., Lewis, A.G., Cohen, E.B., Li, B., et al. The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 19 (2014), 1050–1057.
62. Sung, M.M., Soltys, C.L., Masson, G., Boisvenue, J.J., Dyck, J.R., Improved cardiac metabolism and activation of the RISK pathway contributes to improved post-ischemic recovery in calorie restricted mice. J. Mol. Med. (Berl). 89 (2011), 291–302.
63. Taegtmeyer, H., Young, M.E., Lopaschuk, G.D., Abel, E.D., Brunengraber, H., Darley-Usmar, V., et al. Assessing cardiac metabolism: a scientific statement from the american heart association. Circ. Res. 118 (2016), 1659–1701.
64. Timmers, L., Henriques, J.P., de Kleijn, D.P., Devries, J.H., Kemperman, H., Steendijk, P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53 (2009), 501–510.
65. Tuunanen, H., Engblom, E., Naum, A., Nagren, K., Scheinin, M., Hesse, B., et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118 (2008), 1250–1258.
66. Ussher, J.R., Deciphering ventricular GLP-1 action: time for a change of heart. Am. J. Physiol. Heart Circ. Physiol. 307 (2014), H1390–2.
67. Ussher, J.R., Baggio, L.L., Campbell, J.E., Mulvihill, E.E., Kim, M., Kabir, M.G., et al. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol. Metab. 3 (2014), 507–517.
68. Ussher, J.R., Drucker, D.J., Cardiovascular biology of the incretin system. Endocr. Rev. 33 (2012), 187–215.
69. Ussher, J.R., Drucker, D.J., Cardiovascular actions of incretin-based therapies. Circ. Res. 114 (2014), 1788–1803.
70. Ussher, J.R., Elmariah, S., Gerszten, R.E., Dyck, J.R., The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J. Am. Coll. Cardiol. 68 (2016), 2850–2870.
71. Ussher, J.R., Fillmore, N., Keung, W., Mori, J., Beker, D.L., Wagg, C.S., et al. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice. Can. J. Cardiol. 30 (2014), 940–944.
72. Ussher, J.R., Koves, T.R., Jaswal, J.S., Zhang, L., Ilkayeva, O., Dyck, J.R., et al. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes 58 (2009), 1766–1775.
73. Ussher, J.R., Sutendra, G., Jaswal, J.S., The impact of current and novel anti-diabetic therapies on cardiovascular risk. Future Cardiol. 8 (2012), 895–912.
74. Ussher, J.R., Wang, W., Gandhi, M., Keung, W., Samokhvalov, V., Oka, T., et al. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc. Res. 94 (2012), 359–369.
75. Wisneski, J.A., Gertz, E.W., Neese, R.A., Gruenke, L.D., Morris, D.L., Craig, J.C., Metabolic fate of extracted glucose in normal human myocardium. J. Clin. Invest. 76 (1985), 1819–1827.
76. Wisneski, J.A., Stanley, W.C., Neese, R.A., Gertz, E.W., Effects of acute hyperglycemia on myocardial glycolytic activity in humans. J. Clin. Invest. 85 (1990), 1648–1656.
77. Woo, J.S., Kim, W., Ha, S.J., Kim, J.B., Kim, S.J., Kim, W.S., et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 2252–2260.
78. Wright, J.J., Kim, J., Buchanan, J., Boudina, S., Sena, S., Bakirtzi, K., et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc. Res. 82 (2009), 351–360.
79. Yan, J., Young, M.E., Cui, L., Lopaschuk, G.D., Liao, R., Tian, R., Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 119 (2009), 2818–2828.
80. Zhang, L., Jaswal, J.S., Ussher, J.R., Sankaralingam, S., Wagg, C., Zaugg, M., et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ. Heart Fail 6 (2013), 1039–1048.
81. Zhao, P., Zhang, J., Yin, X.G., Maharaj, P., Narraindoo, S., Cui, L.Q., et al. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci. 92 (2013), 633–638.
82. Zhao, T., Parikh, P., Bhashyam, S., Bolukoglu, H., Poornima, I., Shen, Y.T., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317 (2006), 1106–1113.
83. Zlobine, I., Gopal, K., Ussher, J.R., Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim. Biophys. Acta 1861 (2016), 1555–1568.